Q1 EPS Forecast for Avidity Biosciences Lowered by Analyst

Avidity Biosciences, Inc. (NASDAQ:RNA) – Equities researchers at Leerink Partnrs lowered their Q1 2025 earnings estimates for Avidity Biosciences in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of ($0.88) for the quarter, down from their prior forecast of ($0.84). The consensus estimate for Avidity Biosciences’ current full-year earnings is ($2.89) per share. Leerink Partnrs also issued estimates for Avidity Biosciences’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.84) EPS and FY2026 earnings at ($4.82) EPS.

A number of other equities research analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $72.00 price objective on shares of Avidity Biosciences in a research report on Friday, January 10th. Chardan Capital reaffirmed a “buy” rating and set a $65.00 target price on shares of Avidity Biosciences in a report on Wednesday, November 13th. The Goldman Sachs Group started coverage on Avidity Biosciences in a research note on Tuesday, September 24th. They issued a “buy” rating and a $59.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price objective on shares of Avidity Biosciences in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $67.00 target price on shares of Avidity Biosciences in a research report on Tuesday. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $65.80.

Avidity Biosciences Price Performance

RNA stock opened at $30.84 on Wednesday. Avidity Biosciences has a 12 month low of $9.93 and a 12 month high of $56.00. The firm has a 50 day simple moving average of $35.22 and a 200 day simple moving average of $41.25.

Avidity Biosciences (NASDAQ:RNA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.14. Avidity Biosciences had a negative return on equity of 27.66% and a negative net margin of 2,772.45%. The business had revenue of $2.34 million during the quarter, compared to analysts’ expectations of $7.09 million.

Insider Activity at Avidity Biosciences

In other Avidity Biosciences news, CEO Sarah Boyce sold 31,855 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $32.66, for a total value of $1,040,384.30. Following the completion of the sale, the chief executive officer now directly owns 265,308 shares in the company, valued at $8,664,959.28. The trade was a 10.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider W. Michael Flanagan sold 12,742 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $32.66, for a total transaction of $416,153.72. Following the transaction, the insider now owns 72,647 shares in the company, valued at approximately $2,372,651.02. This trade represents a 14.92 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,071 shares of company stock valued at $4,679,174. Insiders own 3.68% of the company’s stock.

Institutional Trading of Avidity Biosciences

Large investors have recently made changes to their positions in the stock. PEAK6 Investments LLC lifted its holdings in Avidity Biosciences by 4.9% in the 3rd quarter. PEAK6 Investments LLC now owns 7,343 shares of the biotechnology company’s stock worth $337,000 after purchasing an additional 343 shares during the last quarter. Aaron Wealth Advisors LLC lifted its stake in shares of Avidity Biosciences by 6.6% in the fourth quarter. Aaron Wealth Advisors LLC now owns 8,102 shares of the biotechnology company’s stock worth $236,000 after buying an additional 504 shares during the last quarter. National Bank of Canada FI bought a new stake in shares of Avidity Biosciences during the 3rd quarter worth $27,000. Allspring Global Investments Holdings LLC acquired a new position in Avidity Biosciences in the 3rd quarter valued at $30,000. Finally, Values First Advisors Inc. bought a new position in Avidity Biosciences in the 3rd quarter worth $32,000.

Avidity Biosciences Company Profile

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.